228 results about "Clinical manifestation" patented technology

A clinical reference and education system and method of use, wherein medical condition diagnosis information is gathered, stored, and distributed. More specifically, information regarding clinical/pathological differential analyses, key facts, clinical presentations, pathology features, imaging findings, anatomy information, medical references with abstracts, expert imaging center information, continuing medical education information, and related data is made available in electronic and printed forms via a general infrastructure of the present system.

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.

Systems and methods for developing a brain state analysis system using subject EEG data are provided. The analysis system distinguishes clinical from subclinical electrographic seizures and optionally distinguishes among different seizure onset characteristics. An algorithm trained on only clinical electrographic seizures may predict clinical seizures more accurately with fewer perceived false positives. In addition, algorithms trained on a particular onset condition may distinguish and advise on that onset condition when used by the patient.

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

A method of comparing a patient's neurological data to data that is indicative of the patient's clinical manifestation of a seizure. In some embodiments, the method includes the steps of monitoring neurological data from a patient indicative of the patient's propensity for having a seizure; automatically recording clinical manifestation data from the patient that may be indicative of the occurrence of a clinical seizure; and analyzing the automatically recorded clinical manifestation data and the monitored neurological data to determine if one of the clinical manifestation data and the neurological data indicates the occurrence of a seizure while the other does not. Systems are described including a monitoring device having a communication assembly for receiving neurological data transmitted external to a patient from a transmitter implanted in a patient; a processor that processes the neurological data to estimate the patient's brain state; and an assembly for automatically recording clinical manifestation data in response to a brain state estimate by the processor.

The present invention relates to the use of an immunogenic composition that comprises a salmonella antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection, even more preferably PCVAD. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of salmonella antigen, preferably a salmonella vaccine, lessens the incidence and reduces the severity of PCVAD.

The present invention relates to the use of an immunogenic composition that comprises a PCV2 antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with an enteric infection, even more preferably, with enteric disease. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of PCV2 antigen, preferably ORF2 of PCV2, lessens the incidence and reduces the severity of the enteric disease.

This invention related to methods and assays for screening for, identifying, and predicting the severity and clinical manifestations of systemic lupus erythematosus (SLE). Specifically, this invention provides various biomarkers for the prediction of flares of the disease both in number and severity, as well as clinical manifestations of the disease, and methods of using these biomarkers to correctly subclassify patients with this disease, and prescribe appropriate treatment. The invention also provides for biomarkers of lupus disease activity, i.e., flares, as well as biomarkers for the prediction of future flares, and methods of using these biomarkers. The invention also provides, in these biomarkers, targets and methods for drug development and basic research for SLE.

The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.

The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention alsorelates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manitfesation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

The present invention provides methods, systems, and code for accurately classifying or diagnosing a sample from an individual as an IBS sample. The methods and systems of the present invention are useful for ruling out one or more diseases or disorders that share a similar clinical presentation as IBS followed by identifying (i.e., ruling in) IBS using statistical algorithm(s) and/or empirical data. In particular, the methods and systems of the present invention use a first combination of learning statistical classifier systems to rule out IBD with an accuracy of greater than about 90% and a second combination of learning statistical classifier systems to rule in IBS in a non-IBD sample with an accuracy of greater than about 80%.

Animal models for severe acute respiratory syndrome-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness. The severity of the disease developed in these transgenic mice, AC70 in particular, makes these mouse models valuable not only for evaluating the efficacy of antivirals and vaccines, but also for studying SARS coronavirus pathogenesis and infection by other coronaviruses utilizing human ACE2 for viral entry into cells.

The embodiment of the invention provides a disease inference system based on a medical knowledge graph, wherein the system includes an acquisition module for obtaining diagnosis evidence information of patients, and a disease inference module for querying the medical knowledge graph according to the diagnosis evidence information of the patients, obtaining the clinical manifestation correspondingto the diagnosis evidence information, querying the medical knowledge graph according to the clinical manifestation and obtaining disease information corresponding to the clinical manifestation; the medical knowledge graph is a mapping map established in advance according to a disease knowledge base and the professional knowledge of doctors and used for representing the interrelationship among thediagnosis evidence entity, the clinical manifestation entity and the suspected disease entity.

The invention belongs to the field of life science, relates to an application of a probiotic preparation in treating and preventing vascular dementia, in particular to a new application of medicine for preventing and treating vascular dementia through clostridium butyricum. Vascular dementia is brain tissue damage existing on the basis of multiple cerebrovascular diseases and the syndrome with cognition impairment as main clinical manifestation. The probiotic preparation for preventing and treating vascular dementia comprises medicine, healthcare products and drinks. No toxic or side effect is found. Intestinal flora is creatively adopted as treatment target points, a new pattern for preventing and treating vascular dementia is created, disease symptoms are relieved, nerve cell damage is retarded, good social and economic benefits are achieved, and the probiotic preparation is worthy of being applied and popularized.

The invention relates to a tea for enlivening spleens and a production method of the tea. The tea is produced by the following components at a certain weight ratio: radix astragali, bighead atractylodes rhizome, angelica sinensis, rhizoma alismatis, radix bupleuri, radix paeoniae alba, tangerine peel, codonopsis pilosula, common yam rhizome, stir-fried fructus aurantii, rhizoma cyperi, dark plum, trichosanthes kirilowii maxim, rhizoma atractylodis, rhizoma acori graminei, mangnolia officinalis, medicated leaven, hawthorn, poria cocos, and black tea. The tea is reasonable in formulation, simple to produce, easy to preserve, appropriate in four seasons, convenient to drink, and appropriate in taste, has the function of integrating all medicine components for enlivening the spleens and allowing the medicine components to exert a synergetic effect, thereby realizing efficacies of replenishing qi, invigorating the spleens, removing dampness, promoting diuresis, regulating middle energizers, promoting the circulation of qi, dispelling phlegm, inducing reuscitation, removing blood stasis, and eliminating stagnation; people with pathogenic dampness and the encumbered spleens can select according to different clinical manifestations and symptoms; and the incidence of diseases with the major manifestations of tiredness and sleepiness induced by various causes can be reduced.

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.

The invention discloses anti-wrinkle essence which comprises a functional component, an auxiliary component and water, wherein the functional component comprises the following raw materials by weight percent: 0.03-0.3% of small-molecule sodium hyaluronate, 0.3-3% of acetyl chitosamine, 0.3-3% of an alpinia galangal extract, 1-3% of acetyl tetrapeptide-9, 1-5% of a chondrus crispus extract, 0.5-2% of a hibiscus abelmoschus seed extract, 2-6% of glycerin and 2-6% of butanediol. The adopted alpinia galangal extract is a natural plant active ingredient capable of promoting the synthesis of macromolecule hyaluronic acid. A small molecule or fragment hyaluronic acid in the skin can be transformed into the macromolecule hyaluronic acid, so that the problem that hyaluronic acid is difficult to absorb is effectively solved. The essence has excellent clinical manifestation in the skincare effects of preserving moisture, resisting ageing and removing winkles.

Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.

The invention relates to a method for establishing an artery ischemia model of a brain of a rhesus monkey and an evaluation method. The constructing method adopts the mode of directly puncturing femoral arteries of an experimental monkey to perform the intravascular interventional operation under the direct view of a digital subtraction angiography, and establishes the chronic cerebral infarctionprimate model by using a micro-catheter to block the arteries in the brain of the experimental monkey and controlling ischemia time. The model is a quite reasonable cerebral ischemia-reperfusion animal model, and the pathological characteristics of the monkey cerebral injury model established by the method are similar to clinical manifestation; and moreover, the model is stable and reliable and issuitable for all kinds of curing therapeutic research and related basic research.

The invention discloses an adjuvant for improving the effect of a porcine reproductive and respiratory syndrome (PRRSV) inactivated vaccine, a preparation method thereof and application thereof and relates to the preparation method and steps of Hemagglutinating virus of Japan envelope (HVJ-E) and application of a medicament for improving the effect of the PRRSV inactivated vaccine. The preparation method of adjuvant comprises the following steps of: breeding Hemagglutinating virus of Japan (HVJ) by using an SPF chick embryo, and then concentrating, purifying, counting and inactivating the HVJ to prepare the Hemagglutinating virus of Japan envelope (HVJ-E); immunizing PRRSV negative pigs with the HVJ-E and the PRRSV inactivated vaccine together, and setting a PBS contrast group and a PRRSV inactivated vaccine group at the same time, wherein compared with the contrast group, the HVJ-E and PRRSV inactivated vaccine group can obviously improve the response level of hunoral immunity and cellular immunity of the pigs; and after immunizing, expelling toxin by using a PRRSV virulent strain (JXA1), wherein the result shows that the clinical manifestations and the weight increasing of the HVJ-E and PRRSV inactivated vaccine group are better than those of the contrast group, and the generated viremiavirusemia rate, toxin expelling rate and virus distribution rate are obviously reduced when compared with the contrast group. The adjuvant of the invention has the advantages of convenient production and low cost and is suitable for large-scale production.